DCOY Company Profile and Key Details

Decoy Therapeutics Inc. (NASDAQ:DCOY) closed at $3.85 USD, gaining $0.75 (24.19%) from the previous close of $3.10. The stock is currently mid-range between its 52-week high and low $2.18 and $55.92. With a market capitalization of about $2.05 million, Decoy Therapeutics Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.56). Key stats such as the average daily volume over the past year has been around 1.91 million shares, trading with heavier-than-usual volume. Headquartered in Houston, TX, Decoy Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Frederick E. Pierce, the company employs approximately 11 people and listed since January 29, 2015. Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs.

DCOY has shown mixed momentum, gaining 0.04% over the past week and -80.16% over the past quarter, though year-to-date performance is up 25.66%. Short-term trend indicators are bullishly aligned (SMA20 -6.37%, SMA50 -8.37%, SMA200 -87.47%). The stock’s 14-day RSI is 43.14 (neutral), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -98.03% below its high and over 32.67% above its low. Average 10-day trading volume of 57.96 thousand shares is below the 3-month average of 254.22 thousand, indicating normal recent market interest.

Decoy Therapeutics Inc. trades at a P/E ratio of -0.13, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.47 suggesting the stock is closer to book value. The P/FCF stands at -0.24, also above market averages.

Decoy Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $22.24. This means the shares are trading below this model’s fair value.

Decoy Therapeutics Inc. has 655.18 thousand shares outstanding. The public float is 652.07 thousand shares, elevated short interest at 4.77% of float. This equals 25.25 thousand shares. The short ratio is 0.27 days. Institutional investors hold 5.77% of the float. Insiders own 0.28%.